<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="pmcid: 7128473S2589-5559(20)30047-1 doi: 10.1016/j.jhepr.2020.100113100113 : Review Care of patients with" exact="liver disease" post="during the COVID-19 pandemic: EASL-ESCMID position paper BoettlerTobias1NewsomePhilip N.23MondelliMario"/>
 <result pre="7128473S2589-5559(20)30047-1 doi: 10.1016/j.jhepr.2020.100113100113 : Review Care of patients with liver" exact="disease" post="during the COVID-19 pandemic: EASL-ESCMID position paper BoettlerTobias1NewsomePhilip N.23MondelliMario"/>
 <result pre="article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract Summary The" exact="coronavirus disease" post="2019 (COVID-19) pandemic poses an enormous challenge to healthcare"/>
 <result pre="under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract Summary The coronavirus" exact="disease" post="2019 (COVID-19) pandemic poses an enormous challenge to healthcare"/>
 <result pre="have been identified as populations at risk of a severe" exact="disease" post="course. It remains unclear at this point to what"/>
 <result pre="course. It remains unclear at this point to what extent" exact="chronic" post="liver diseases should be considered as risk factors, due"/>
 <result pre="to a shortage of appropriate studies. However, patients with advanced" exact="liver disease" post="and those after liver transplantation represent vulnerable patient cohorts"/>
 <result pre="a shortage of appropriate studies. However, patients with advanced liver" exact="disease" post="and those after liver transplantation represent vulnerable patient cohorts"/>
 <result pre="transplantation represent vulnerable patient cohorts with an increased risk of" exact="infection" post="and/or a severe course of COVID-19. In addition, the"/>
 <result pre="resources which may negatively impact the care of patients with" exact="chronic" post="liver disease that continue to require medical attention. Thus,"/>
 <result pre="which may negatively impact the care of patients with chronic" exact="liver disease" post="that continue to require medical attention. Thus, the challenge"/>
 <result pre="may negatively impact the care of patients with chronic liver" exact="disease" post="that continue to require medical attention. Thus, the challenge"/>
 <result pre="ACE2, angiotensin-converting enzyme 2 ACE-I, angiotensin-converting enzyme inhibitor ACLF, acute-on-chronic" exact="liver failure" post="ALT, alanine aminotransferase AST, aspartate aminotransferase COVID-19, coronavirus disease"/>
 <result pre="acute-on-chronic liver failure ALT, alanine aminotransferase AST, aspartate aminotransferase COVID-19," exact="coronavirus disease" post="2019 EGD, esophagogastroduodenoscopy ERC, endoscopic retrograde cholangiography HCC, hepatocellular"/>
 <result pre="liver failure ALT, alanine aminotransferase AST, aspartate aminotransferase COVID-19, coronavirus" exact="disease" post="2019 EGD, esophagogastroduodenoscopy ERC, endoscopic retrograde cholangiography HCC, hepatocellular"/>
 <result pre="coronavirus disease 2019 EGD, esophagogastroduodenoscopy ERC, endoscopic retrograde cholangiography HCC," exact="hepatocellular carcinoma" post="MELD, model for end-stage liver disease NAFLD, non-alcoholic fatty"/>
 <result pre="disease 2019 EGD, esophagogastroduodenoscopy ERC, endoscopic retrograde cholangiography HCC, hepatocellular" exact="carcinoma" post="MELD, model for end-stage liver disease NAFLD, non-alcoholic fatty"/>
 <result pre="ERC, endoscopic retrograde cholangiography HCC, hepatocellular carcinoma MELD, model for" exact="end-stage liver disease" post="NAFLD, non-alcoholic fatty liver disease NASH, non-alcoholic steatohepatitis NUC,"/>
 <result pre="endoscopic retrograde cholangiography HCC, hepatocellular carcinoma MELD, model for end-stage" exact="liver disease" post="NAFLD, non-alcoholic fatty liver disease NASH, non-alcoholic steatohepatitis NUC,"/>
 <result pre="retrograde cholangiography HCC, hepatocellular carcinoma MELD, model for end-stage liver" exact="disease" post="NAFLD, non-alcoholic fatty liver disease NASH, non-alcoholic steatohepatitis NUC,"/>
 <result pre="HCC, hepatocellular carcinoma MELD, model for end-stage liver disease NAFLD," exact="non-alcoholic fatty liver" post="disease NASH, non-alcoholic steatohepatitis NUC, nucleoside analogue PIs, protease"/>
 <result pre="hepatocellular carcinoma MELD, model for end-stage liver disease NAFLD, non-alcoholic" exact="fatty liver disease" post="NASH, non-alcoholic steatohepatitis NUC, nucleoside analogue PIs, protease inhibitors"/>
 <result pre="carcinoma MELD, model for end-stage liver disease NAFLD, non-alcoholic fatty" exact="liver disease" post="NASH, non-alcoholic steatohepatitis NUC, nucleoside analogue PIs, protease inhibitors"/>
 <result pre="MELD, model for end-stage liver disease NAFLD, non-alcoholic fatty liver" exact="disease" post="NASH, non-alcoholic steatohepatitis NUC, nucleoside analogue PIs, protease inhibitors"/>
 <result pre="analogue PIs, protease inhibitors RdRp, RNA-dependent RNA polymerase SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2 ULN, upper limit of normal"/>
 <result pre="PIs, protease inhibitors RdRp, RNA-dependent RNA polymerase SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2 ULN, upper limit of normal Introduction"/>
 <result pre="protease inhibitors RdRp, RNA-dependent RNA polymerase SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2 ULN, upper limit of normal Introduction Coronavirus"/>
 <result pre="RNA polymerase SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 ULN," exact="upper" post="limit of normal Introduction Coronavirus disease 2019 (COVID-19) is"/>
 <result pre="respiratory syndrome coronavirus 2 ULN, upper limit of normal Introduction" exact="Coronavirus disease" post="2019 (COVID-19) is caused by the recently identified coronavirus,"/>
 <result pre="syndrome coronavirus 2 ULN, upper limit of normal Introduction Coronavirus" exact="disease" post="2019 (COVID-19) is caused by the recently identified coronavirus,"/>
 <result pre="2019 (COVID-19) is caused by the recently identified coronavirus, severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms associated with COVID-19"/>
 <result pre="(COVID-19) is caused by the recently identified coronavirus, severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Symptoms associated with COVID-19 are"/>
 <result pre="is caused by the recently identified coronavirus, severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Symptoms associated with COVID-19 are mostly"/>
 <result pre="less frequently.1 While symptoms remain mild throughout the course of" exact="infection" post="in the majority of patients, older patients were identified"/>
 <result pre="were identified to be at higher risk of a fatal" exact="disease" post="course, with hypertension, diabetes and coronary heart disease being"/>
 <result pre="at higher risk of a fatal disease course, with hypertension," exact="diabetes" post="and coronary heart disease being the most frequent comorbidities"/>
 <result pre="risk of a fatal disease course, with hypertension, diabetes and" exact="coronary heart disease" post="being the most frequent comorbidities in these cohorts.2,3 COVID-19"/>
 <result pre="of a fatal disease course, with hypertension, diabetes and coronary" exact="heart" post="disease being the most frequent comorbidities in these cohorts.2,3"/>
 <result pre="a fatal disease course, with hypertension, diabetes and coronary heart" exact="disease" post="being the most frequent comorbidities in these cohorts.2,3 COVID-19"/>
 <result pre="comorbidities in these cohorts.2,3 COVID-19 and the liver While pre-existing" exact="liver disease" post="is not specifically listed in the published cohort studies,"/>
 <result pre="in these cohorts.2,3 COVID-19 and the liver While pre-existing liver" exact="disease" post="is not specifically listed in the published cohort studies,"/>
 <result pre="or whether they mirror a severe inflammatory response (hypoalbuminemia) with" exact="disseminated intravascular coagulation" post="(thrombocytopenia). Possibly, patients with advanced chronic liver disease are"/>
 <result pre="(hypoalbuminemia) with disseminated intravascular coagulation (thrombocytopenia). Possibly, patients with advanced" exact="chronic" post="liver disease are at increased risk of infection due"/>
 <result pre="with disseminated intravascular coagulation (thrombocytopenia). Possibly, patients with advanced chronic" exact="liver disease" post="are at increased risk of infection due to cirrhosis-associated"/>
 <result pre="disseminated intravascular coagulation (thrombocytopenia). Possibly, patients with advanced chronic liver" exact="disease" post="are at increased risk of infection due to cirrhosis-associated"/>
 <result pre="with advanced chronic liver disease are at increased risk of" exact="infection" post="due to cirrhosis-associated immune dysfunction.4 The same could be"/>
 <result pre="true for patients after liver transplantation and possibly those with" exact="autoimmune" post="liver diseases who receive immunosuppressive therapies. However, currently, there"/>
 <result pre="diseases who receive immunosuppressive therapies. However, currently, there are only" exact="limited" post="data available linking underlying liver diseases with the course"/>
 <result pre="available linking underlying liver diseases with the course of SARS-CoV-2" exact="infection" post="and there are many open questions (Box 1). Chronic"/>
 <result pre="SARS-CoV-2 infection and there are many open questions (Box 1)." exact="Chronic" post="hepatitis B virus infection for example, which is more"/>
 <result pre="infection and there are many open questions (Box 1). Chronic" exact="hepatitis" post="B virus infection for example, which is more prevalent"/>
 <result pre="there are many open questions (Box 1). Chronic hepatitis B" exact="virus infection" post="for example, which is more prevalent in China than"/>
 <result pre="are many open questions (Box 1). Chronic hepatitis B virus" exact="infection" post="for example, which is more prevalent in China than"/>
 <result pre="the disease.5,6 These may be associated with a macrophage activation" exact="syndrome" post="in the context of a hyperinflammatory syndrome characterised by"/>
 <result pre="a macrophage activation syndrome in the context of a hyperinflammatory" exact="syndrome" post="characterised by a cytokine storm with multi-organ failure.7 On"/>
 <result pre="a cytokine storm with multi-organ failure.7 On the other hand," exact="systemic" post="viral infections are often associated with transient elevations of"/>
 <result pre="cytokine storm with multi-organ failure.7 On the other hand, systemic" exact="viral" post="infections are often associated with transient elevations of transaminases"/>
 <result pre="storm with multi-organ failure.7 On the other hand, systemic viral" exact="infections" post="are often associated with transient elevations of transaminases which"/>
 <result pre="the other hand, systemic viral infections are often associated with" exact="transient" post="elevations of transaminases which may reflect general immune activation"/>
 <result pre="may also be the case in patients with COVID-19 where" exact="liver failure" post="has not been specifically reported, even in the most"/>
 <result pre="the most severe and fatal courses of disease.1,2 However, signs" exact="of liver" post="dysfunction may occur in critically ill patients with COVID-19,8"/>
 <result pre="ill patients with COVID-19,8 as reviewed in.9,10 Whether patients with" exact="cirrhosis" post="and COVID-19 are at increased risk of decompensation or"/>
 <result pre="are at increased risk of decompensation or development of acute-on-chronic" exact="liver failure" post="(ACLF), as has been shown for influenza infection,11 remains"/>
 <result pre="to be expressed on cholangiocytes,13,14 which may explain cases of" exact="viral" post="shedding into the faeces.15,16 How far observations from Asian"/>
 <result pre="remains to be determined, but it appears unlikely that SARS-CoV-2" exact="infection" post="causes liver damage to an amount that substantially contributes"/>
 <result pre="damage to an amount that substantially contributes to the overall" exact="disease" post="burden. Box 1 Open questions for liver-related basic/translational research"/>
 <result pre="Open questions for liver-related basic/translational research regarding COVID-19. ACLF, acute-on-chronic" exact="liver failure;" post="COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome"/>
 <result pre="liver-related basic/translational research regarding COVID-19. ACLF, acute-on-chronic liver failure; COVID-19," exact="coronavirus disease" post="2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Aside"/>
 <result pre="basic/translational research regarding COVID-19. ACLF, acute-on-chronic liver failure; COVID-19, coronavirus" exact="disease" post="2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Aside"/>
 <result pre="ACLF, acute-on-chronic liver failure; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2. Aside from the direct implications"/>
 <result pre="acute-on-chronic liver failure; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2. Aside from the direct implications of"/>
 <result pre="liver failure; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2. Aside from the direct implications of liver"/>
 <result pre="acute respiratory syndrome coronavirus 2. Aside from the direct implications" exact="of liver" post="disease on the course of COVID-19 or vice versa,"/>
 <result pre="respiratory syndrome coronavirus 2. Aside from the direct implications of" exact="liver disease" post="on the course of COVID-19 or vice versa, there"/>
 <result pre="syndrome coronavirus 2. Aside from the direct implications of liver" exact="disease" post="on the course of COVID-19 or vice versa, there"/>
 <result pre="underestimated, it remains important to maintain care of patients with" exact="chronic" post="liver disease and to identify potential ways to prioritise"/>
 <result pre="it remains important to maintain care of patients with chronic" exact="liver disease" post="and to identify potential ways to prioritise care of"/>
 <result pre="remains important to maintain care of patients with chronic liver" exact="disease" post="and to identify potential ways to prioritise care of"/>
 <result pre="ways to prioritise care of these patients in times of" exact="limited" post="healthcare resources. Considerations for patients with chronic liver disease"/>
 <result pre="in times of limited healthcare resources. Considerations for patients with" exact="chronic" post="liver disease and patients after liver transplantation The recommendations"/>
 <result pre="times of limited healthcare resources. Considerations for patients with chronic" exact="liver disease" post="and patients after liver transplantation The recommendations provided here"/>
 <result pre="of limited healthcare resources. Considerations for patients with chronic liver" exact="disease" post="and patients after liver transplantation The recommendations provided here"/>
 <result pre="recommendations provided here address the specific characteristics of patients with" exact="liver disease" post="and are meant to provide additional guidance for the"/>
 <result pre="provided here address the specific characteristics of patients with liver" exact="disease" post="and are meant to provide additional guidance for the"/>
 <result pre="to provide additional guidance for the care of these patients." exact="General" post="recommendations and guidelines with regards to prevention, diagnosis and"/>
 <result pre="Outpatient care The management and surveillance of patients with advanced" exact="liver disease" post="and those receiving immunosuppressive treatment is often performed in"/>
 <result pre="care The management and surveillance of patients with advanced liver" exact="disease" post="and those receiving immunosuppressive treatment is often performed in"/>
 <result pre="are currently also COVID-19 hotspots, thus, potentially putting outpatients with" exact="chronic" post="liver diseases at risk of nosocomial infections. In addition,"/>
 <result pre="potentially putting outpatients with chronic liver diseases at risk of" exact="nosocomial infections." post="In addition, hospital staffs face challenges such as long"/>
 <result pre="burden. In case of COVID-19 in patients with more advanced" exact="chronic" post="liver disease, we recommend admission for inpatient care depending"/>
 <result pre="In case of COVID-19 in patients with more advanced chronic" exact="liver disease," post="we recommend admission for inpatient care depending on the"/>
 <result pre="chart for the prioritisation of patient care in patients with" exact="chronic" post="liver disease. The individual management of these patients strongly"/>
 <result pre="for the prioritisation of patient care in patients with chronic" exact="liver disease." post="The individual management of these patients strongly depends on"/>
 <result pre="not be able and transplantation activities might be reduced. COVID-19," exact="coronavirus disease" post="2019; HCC, hepatocellular carcinoma; NAFLD, non-alcoholic fatty liver disease;"/>
 <result pre="be able and transplantation activities might be reduced. COVID-19, coronavirus" exact="disease" post="2019; HCC, hepatocellular carcinoma; NAFLD, non-alcoholic fatty liver disease;"/>
 <result pre="transplantation activities might be reduced. COVID-19, coronavirus disease 2019; HCC," exact="hepatocellular carcinoma;" post="NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; SARS-CoV-2,"/>
 <result pre="be reduced. COVID-19, coronavirus disease 2019; HCC, hepatocellular carcinoma; NAFLD," exact="non-alcoholic fatty liver" post="disease; NASH, non-alcoholic steatohepatitis; SARS-CoV-2, severe acute respiratory syndrome"/>
 <result pre="reduced. COVID-19, coronavirus disease 2019; HCC, hepatocellular carcinoma; NAFLD, non-alcoholic" exact="fatty liver disease;" post="NASH, non-alcoholic steatohepatitis; SARS-CoV-2, severe acute respiratory syndrome coronavirus"/>
 <result pre="COVID-19, coronavirus disease 2019; HCC, hepatocellular carcinoma; NAFLD, non-alcoholic fatty" exact="liver disease;" post="NASH, non-alcoholic steatohepatitis; SARS-CoV-2, severe acute respiratory syndrome coronavirus"/>
 <result pre="NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2. Reduction of direct exposure Physical"/>
 <result pre="non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2. Reduction of direct exposure Physical distancing"/>
 <result pre="fatty liver disease; NASH, non-alcoholic steatohepatitis; SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2. Reduction of direct exposure Physical distancing has"/>
 <result pre="This measure aims to prevent a rapid increase in SARS-CoV-2" exact="infections" post="in the general population with the overall goal of"/>
 <result pre="the amount of individual contacts, physicians are at risk of" exact="infection" post="and subsequently also dissemination of the virus. Thus, it"/>
 <result pre="patients that need to be protected from a potentially harmful" exact="infection" post="and guide them through the pandemic, explaining the future"/>
 <result pre="for situations like these in the future. Patients with compensated" exact="liver disease" post="General considerations •Visits to specialised centres can be postponed."/>
 <result pre="situations like these in the future. Patients with compensated liver" exact="disease" post="General considerations •Visits to specialised centres can be postponed."/>
 <result pre="like these in the future. Patients with compensated liver disease" exact="General" post="considerations •Visits to specialised centres can be postponed. •Use"/>
 <result pre="possible. •Routine laboratory testing can be performed locally, e.g. through" exact="primary" post="care physician, and its frequency needs careful individual risk-benefit"/>
 <result pre="its frequency needs careful individual risk-benefit considerations. Specific considerations •Chronic" exact="viral hepatitis" post="does not appear to increase the risk of a"/>
 <result pre="frequency needs careful individual risk-benefit considerations. Specific considerations •Chronic viral" exact="hepatitis" post="does not appear to increase the risk of a"/>
 <result pre="patients under antiviral therapy, send follow-up-prescriptions by mail. •Patients with" exact="non-alcoholic fatty liver" post="disease (NAFLD) or steatohepatitis (NASH) may suffer from metabolic"/>
 <result pre="under antiviral therapy, send follow-up-prescriptions by mail. •Patients with non-alcoholic" exact="fatty liver disease" post="(NAFLD) or steatohepatitis (NASH) may suffer from metabolic comorbidities"/>
 <result pre="antiviral therapy, send follow-up-prescriptions by mail. •Patients with non-alcoholic fatty" exact="liver disease" post="(NAFLD) or steatohepatitis (NASH) may suffer from metabolic comorbidities"/>
 <result pre="therapy, send follow-up-prescriptions by mail. •Patients with non-alcoholic fatty liver" exact="disease" post="(NAFLD) or steatohepatitis (NASH) may suffer from metabolic comorbidities"/>
 <result pre="steatohepatitis (NASH) may suffer from metabolic comorbidities such as diabetes," exact="hypertension" post="and obesity putting them at increased risk of a"/>
 <result pre="(NASH) may suffer from metabolic comorbidities such as diabetes, hypertension" exact="and obesity" post="putting them at increased risk of a severe course"/>
 <result pre="may suffer from metabolic comorbidities such as diabetes, hypertension and" exact="obesity" post="putting them at increased risk of a severe course"/>
 <result pre="risk of a severe course of COVID-19. •In patients with" exact="autoimmune" post="liver disease, we currently advise against reducing immunosuppressive therapy."/>
 <result pre="of a severe course of COVID-19. •In patients with autoimmune" exact="liver disease," post="we currently advise against reducing immunosuppressive therapy. Reductions should"/>
 <result pre="pneumoniae and influenza. •In patients with compensated cirrhosis, consider delaying" exact="hepatocellular carcinoma" post="(HCC) surveillance and screening for varices. Non-invasive risk assessment"/>
 <result pre="and influenza. •In patients with compensated cirrhosis, consider delaying hepatocellular" exact="carcinoma" post="(HCC) surveillance and screening for varices. Non-invasive risk assessment"/>
 <result pre="screening for varices. Non-invasive risk assessment for the presence of" exact="varices" post="should be applied for stratification (thrombocyte count or Baveno"/>
 <result pre="See also section on &quot;liver-related diagnostic procedures&quot;. Patients with decompensated" exact="liver disease" post="General considerations •Care should be maintained according to guidelines"/>
 <result pre="also section on &quot;liver-related diagnostic procedures&quot;. Patients with decompensated liver" exact="disease" post="General considerations •Care should be maintained according to guidelines"/>
 <result pre="section on &quot;liver-related diagnostic procedures&quot;. Patients with decompensated liver disease" exact="General" post="considerations •Care should be maintained according to guidelines but"/>
 <result pre="to patients with poor short-term prognosis including those with acute/acute-on-chronic" exact="liver failure" post="(ALF/ACLF), high model for end-stage liver disease (MELD) score"/>
 <result pre="including those with acute/acute-on-chronic liver failure (ALF/ACLF), high model for" exact="end-stage liver disease" post="(MELD) score (including exceptional MELDs) and HCC at the"/>
 <result pre="those with acute/acute-on-chronic liver failure (ALF/ACLF), high model for end-stage" exact="liver disease" post="(MELD) score (including exceptional MELDs) and HCC at the"/>
 <result pre="with acute/acute-on-chronic liver failure (ALF/ACLF), high model for end-stage liver" exact="disease" post="(MELD) score (including exceptional MELDs) and HCC at the"/>
 <result pre="disease (MELD) score (including exceptional MELDs) and HCC at the" exact="upper" post="limits of the Milan criteria, as transplantation activities/organ donations"/>
 <result pre="for Streptococcus pneumoniae and influenza. •Guidelines on prophylaxis of spontaneous" exact="bacterial" post="peritonitis and hepatic encephalopathy should be closely followed to"/>
 <result pre="Streptococcus pneumoniae and influenza. •Guidelines on prophylaxis of spontaneous bacterial" exact="peritonitis" post="and hepatic encephalopathy should be closely followed to prevent"/>
 <result pre="influenza. •Guidelines on prophylaxis of spontaneous bacterial peritonitis and hepatic" exact="encephalopathy" post="should be closely followed to prevent decompensation and avoid"/>
 <result pre="and avoid admission. •Include testing for SARS-CoV-2 in patients with" exact="acute" post="decompensation or ACLF. Specific considerations for patients actively listed"/>
 <result pre="transplantations should be considered on a case-by-case basis. Patients with" exact="hepatocellular carcinoma" post="•Care should be maintained according to guidelines including continuing"/>
 <result pre="should be considered on a case-by-case basis. Patients with hepatocellular" exact="carcinoma" post="•Care should be maintained according to guidelines including continuing"/>
 <result pre="carcinoma •Care should be maintained according to guidelines including continuing" exact="systemic" post="treatments and evaluation for liver transplantation, but consider minimal"/>
 <result pre="the importance of vaccination for Streptococcus pneumoniae and influenza. •In" exact="stable" post="patients: perform local laboratory testing (including drug levels). •We"/>
 <result pre="Endoscopy Patients without COVID-19: Depending on available resources, screening for" exact="varices" post="by esophagogastroduodenoscopy (EGD) should be reserved for patients at"/>
 <result pre="variceal bleeding, such as patients with a history of variceal" exact="bleeding" post="or signs of significant portal hypertension (ascites, thrombocyte count"/>
 <result pre="with a history of variceal bleeding or signs of significant" exact="portal hypertension" post="(ascites, thrombocyte count &amp;lt;100,000/μl). Non-invasive risk assessment for the"/>
 <result pre="a history of variceal bleeding or signs of significant portal" exact="hypertension" post="(ascites, thrombocyte count &amp;lt;100,000/μl). Non-invasive risk assessment for the"/>
 <result pre="thrombocyte count &amp;lt;100,000/μl). Non-invasive risk assessment for the presence of" exact="varices" post="should be applied for stratification (thrombocyte count or Baveno"/>
 <result pre="stent replacement in patients after liver transplantation or patients with" exact="primary sclerosing cholangitis" post="should be performed after careful individual risk-benefit considerations, including"/>
 <result pre="replacement in patients after liver transplantation or patients with primary" exact="sclerosing cholangitis" post="should be performed after careful individual risk-benefit considerations, including"/>
 <result pre="in patients after liver transplantation or patients with primary sclerosing" exact="cholangitis" post="should be performed after careful individual risk-benefit considerations, including"/>
 <result pre="after careful individual risk-benefit considerations, including risk for nosocomial SARS-CoV-2" exact="infection" post="depending on local COVID-19 burden. Patients with COVID-19: Endoscopic"/>
 <result pre="indications for endoscopic procedures in patients with COVID-19 should be" exact="limited" post="to emergencies such as gastrointestinal bleeding, bacterial cholangitis or"/>
 <result pre="COVID-19 should be limited to emergencies such as gastrointestinal bleeding," exact="bacterial" post="cholangitis or other life-threatening conditions. Ultrasound (HCC surveillance) Patients"/>
 <result pre="should be limited to emergencies such as gastrointestinal bleeding, bacterial" exact="cholangitis" post="or other life-threatening conditions. Ultrasound (HCC surveillance) Patients without"/>
 <result pre="risk, such as patients with elevated alpha-fetoprotein levels, advanced cirrhosis," exact="chronic hepatitis" post="B, NASH/diabetes etc., may be prioritised if resources are"/>
 <result pre="such as patients with elevated alpha-fetoprotein levels, advanced cirrhosis, chronic" exact="hepatitis" post="B, NASH/diabetes etc., may be prioritised if resources are"/>
 <result pre="histological assessment. Biopsy should be deferred in patients with •NAFLD" exact="or chronic" post="viral hepatitis (for grading/staging) •mildly elevated transaminases (e.g. ALT"/>
 <result pre="assessment. Biopsy should be deferred in patients with •NAFLD or" exact="chronic" post="viral hepatitis (for grading/staging) •mildly elevated transaminases (e.g. ALT"/>
 <result pre="Biopsy should be deferred in patients with •NAFLD or chronic" exact="viral hepatitis" post="(for grading/staging) •mildly elevated transaminases (e.g. ALT &amp;lt;3× the"/>
 <result pre="should be deferred in patients with •NAFLD or chronic viral" exact="hepatitis" post="(for grading/staging) •mildly elevated transaminases (e.g. ALT &amp;lt;3× the"/>
 <result pre="hepatitis (for grading/staging) •mildly elevated transaminases (e.g. ALT &amp;lt;3× the" exact="upper" post="limit of normal [ULN]) of unknown aetiology Biopsy should"/>
 <result pre="ALT &amp;gt;5× ULN) of unknown aetiology (in case of suspected" exact="autoimmune" post="liver disease, treatment without histological diagnosis can be considered"/>
 <result pre="&amp;gt;5× ULN) of unknown aetiology (in case of suspected autoimmune" exact="liver disease," post="treatment without histological diagnosis can be considered based on"/>
 <result pre="most patients as •treatment/care for COVID-19 outweighs diagnosis of co-existing" exact="liver disease" post="•systemic inflammation associated with COVID-19 will obscure aetiology-specific histologic"/>
 <result pre="patients as •treatment/care for COVID-19 outweighs diagnosis of co-existing liver" exact="disease" post="•systemic inflammation associated with COVID-19 will obscure aetiology-specific histologic"/>
 <result pre="aetiology-specific histologic characteristics •liver biopsy may represent a risk for" exact="viral" post="transmission (although the virus has so far not been"/>
 <result pre="liver as well). Collaboration with local health care providers and" exact="primary" post="care physicians The necessity to reduce travel and limit"/>
 <result pre="and limit visits to specialised centres is a challenge for" exact="liver disease" post="patients and local health care providers alike. In order"/>
 <result pre="limit visits to specialised centres is a challenge for liver" exact="disease" post="patients and local health care providers alike. In order"/>
 <result pre="of patients with liver diseases. Inpatient care Many patients with" exact="chronic" post="liver disease will continue to require inpatient care during"/>
 <result pre="patients with liver diseases. Inpatient care Many patients with chronic" exact="liver disease" post="will continue to require inpatient care during the COVID-19"/>
 <result pre="with liver diseases. Inpatient care Many patients with chronic liver" exact="disease" post="will continue to require inpatient care during the COVID-19"/>
 <result pre="the COVID-19 crisis for decompensation, cholangitis, rejection or other complications." exact="General" post="measures to prevent SARS-CoV-2 exposure and infection will be"/>
 <result pre="or other complications. General measures to prevent SARS-CoV-2 exposure and" exact="infection" post="will be of utmost importance for these patients. Depending"/>
 <result pre="sustainable, although recent evidence provides somewhat reassuring data regarding the" exact="absence of" post="environmental contamination with SARS-CoV-2 RNA of inanimate surfaces outside"/>
 <result pre="of inanimate surfaces outside patient rooms.20 Wherever possible, patients with" exact="chronic" post="liver disease requiring inpatient care for non-COVID-19 causes should"/>
 <result pre="inanimate surfaces outside patient rooms.20 Wherever possible, patients with chronic" exact="liver disease" post="requiring inpatient care for non-COVID-19 causes should be admitted"/>
 <result pre="surfaces outside patient rooms.20 Wherever possible, patients with chronic liver" exact="disease" post="requiring inpatient care for non-COVID-19 causes should be admitted"/>
 <result pre="due to the contagiousness of the virus, patients with underlying" exact="liver disease" post="will become infected and will subsequently require inpatient care"/>
 <result pre="to the contagiousness of the virus, patients with underlying liver" exact="disease" post="will become infected and will subsequently require inpatient care"/>
 <result pre="a significant difference between these cohorts with regards to underlying" exact="chronic" post="liver disease.21 Whether these observations will also hold up"/>
 <result pre="proven. Until further evidence emerges, we recommend that patients with" exact="chronic" post="liver disease and COVID-19 are admitted for inpatient care"/>
 <result pre="Until further evidence emerges, we recommend that patients with chronic" exact="liver disease" post="and COVID-19 are admitted for inpatient care if they"/>
 <result pre="further evidence emerges, we recommend that patients with chronic liver" exact="disease" post="and COVID-19 are admitted for inpatient care if they"/>
 <result pre="risk factors for a more severe COVID-19 course like hypertension," exact="diabetes" post="or obesity, cirrhosis, HCC or a post-transplant status. Treatment"/>
 <result pre="a clinical isolate of SARS-CoV-2 in vitro24 and to reduce" exact="disease" post="severity of the related MERS-CoV-infection in a non-human primate"/>
 <result pre="remain to be clarified. However, with regards to patients with" exact="chronic" post="liver disease, possible adverse events have to be kept"/>
 <result pre="to be clarified. However, with regards to patients with chronic" exact="liver disease," post="possible adverse events have to be kept in mind."/>
 <result pre="early treatment initiation might also be beneficial to prevent severe" exact="pneumonia" post="in COVID-19. Thus, in patients with liver disease and"/>
 <result pre="to prevent severe pneumonia in COVID-19. Thus, in patients with" exact="liver disease" post="and risk factors for a severe course of the"/>
 <result pre="prevent severe pneumonia in COVID-19. Thus, in patients with liver" exact="disease" post="and risk factors for a severe course of the"/>
 <result pre="for the treatment of COVID-19 and considerations for patients with" exact="liver disease" post="or after liver transplantation. Drug Mechanism of action, rationale"/>
 <result pre="the treatment of COVID-19 and considerations for patients with liver" exact="disease" post="or after liver transplantation. Drug Mechanism of action, rationale"/>
 <result pre="reports with COVID-1926 •No relevant drug-interactions expected34 •No experience in" exact="liver cirrhosis" post="but a NUC might be safer than other drug"/>
 <result pre="with COVID-1926 •No relevant drug-interactions expected34 •No experience in liver" exact="cirrhosis" post="but a NUC might be safer than other drug"/>
 <result pre="than other drug classes based on experience with NUCs in" exact="chronic hepatitis" post="B and C •Liver toxicity (↑ALT) possible Chloroquine/Hydroxychloroquine35 ±"/>
 <result pre="other drug classes based on experience with NUCs in chronic" exact="hepatitis" post="B and C •Liver toxicity (↑ALT) possible Chloroquine/Hydroxychloroquine35 ±"/>
 <result pre="ACE224 •Endosomal acidification fusion inhibitor •Generally used for treatment of" exact="malaria" post="and amoebiasis •In vitro and in vivo data32,36 •Exclude"/>
 <result pre="acidification fusion inhibitor •Generally used for treatment of malaria and" exact="amoebiasis" post="•In vitro and in vivo data32,36 •Exclude G6PD deficiency"/>
 <result pre="malaria and amoebiasis •In vitro and in vivo data32,36 •Exclude" exact="G6PD deficiency" post="before application •Drug-interactions with immunosuppressive drugs: close monitoring of"/>
 <result pre="and amoebiasis •In vitro and in vivo data32,36 •Exclude G6PD" exact="deficiency" post="before application •Drug-interactions with immunosuppressive drugs: close monitoring of"/>
 <result pre="abnormalities and is an extremely rare cause of clinically apparent" exact="acute" post="liver injury (LiverTox). Lopinavir/ritonavir •Lopinavir/ritonavir are approved PIs for"/>
 <result pre="are required for calcineurin-inhibitors (cyclosporin, tacrolimus)34 •Data for patients with" exact="liver cirrhosis" post="exist38 •The risk of lopinavir-associated hepatotoxicity in patients with"/>
 <result pre="required for calcineurin-inhibitors (cyclosporin, tacrolimus)34 •Data for patients with liver" exact="cirrhosis" post="exist38 •The risk of lopinavir-associated hepatotoxicity in patients with"/>
 <result pre="•The risk of lopinavir-associated hepatotoxicity in patients with very advanced" exact="liver disease" post="is low •Based on experience with PIs in HCV,"/>
 <result pre="risk of lopinavir-associated hepatotoxicity in patients with very advanced liver" exact="disease" post="is low •Based on experience with PIs in HCV,"/>
 <result pre="•Based on experience with PIs in HCV, patients with decompensated" exact="cirrhosis" post="should not be treated Tocilizumab •Humanised mAb targeting interleukin-6"/>
 <result pre="treated Tocilizumab •Humanised mAb targeting interleukin-6 receptor •Treat cytokine release" exact="syndrome" post="observed in COVID-197 •ALT elevations are frequent but clinically"/>
 <result pre="injury with jaundice seem to be rare39 •Patients with decompensated" exact="cirrhosis" post="should not be treated •Consider risk of HBV reactivation40"/>
 <result pre="receptors to dampen proinflammatory cytokines •Mostly used in patients with" exact="septic shock" post="•Currently NOT recommended by WHO41 •The risk of other"/>
 <result pre="shock •Currently NOT recommended by WHO41 •The risk of other" exact="infections" post="(e.g. SBP) and viral shedding may increase in patents"/>
 <result pre="by WHO41 •The risk of other infections (e.g. SBP) and" exact="viral" post="shedding may increase in patents with decompensated liver cirrhosis"/>
 <result pre="SBP) and viral shedding may increase in patents with decompensated" exact="liver cirrhosis" post="•Consider antimicrobial prophylaxis •Consider risk of HBV reactivation Convalescent"/>
 <result pre="and viral shedding may increase in patents with decompensated liver" exact="cirrhosis" post="•Consider antimicrobial prophylaxis •Consider risk of HBV reactivation Convalescent"/>
 <result pre="plasma •Case reports with COVID-1942 •No experience in patients with" exact="chronic" post="liver disease Umifenovir (Arbidol)∗ •May inhibit viral entry into"/>
 <result pre="•Case reports with COVID-1942 •No experience in patients with chronic" exact="liver disease" post="Umifenovir (Arbidol)∗ •May inhibit viral entry into target cells"/>
 <result pre="reports with COVID-1942 •No experience in patients with chronic liver" exact="disease" post="Umifenovir (Arbidol)∗ •May inhibit viral entry into target cells"/>
 <result pre="in patients with chronic liver disease Umifenovir (Arbidol)∗ •May inhibit" exact="viral" post="entry into target cells and stimulate the immune response,"/>
 <result pre="in liver and intestines in humans. Caution in patients with" exact="liver cirrhosis" post="Favipiravir/favilavir∗ •Guanine analogue, RNA-dependent RNA polymerase (RdRp)- inhibitor, approved"/>
 <result pre="liver and intestines in humans. Caution in patients with liver" exact="cirrhosis" post="Favipiravir/favilavir∗ •Guanine analogue, RNA-dependent RNA polymerase (RdRp)- inhibitor, approved"/>
 <result pre="metabolism •Elevation of ALT and AST possible. •No data in" exact="cirrhosis" post="available Sofosbuvir∗maybe combination with ribavirin •Nucleotide analogue, RdRp-inhibitor •Approved"/>
 <result pre="combination with ribavirin •Nucleotide analogue, RdRp-inhibitor •Approved for treatment of" exact="chronic hepatitis" post="C •In vitro data show binding to SARS-CoV-2 RdRp44"/>
 <result pre="with ribavirin •Nucleotide analogue, RdRp-inhibitor •Approved for treatment of chronic" exact="hepatitis" post="C •In vitro data show binding to SARS-CoV-2 RdRp44"/>
 <result pre="show binding to SARS-CoV-2 RdRp44 •Good experience in patients with" exact="chronic hepatitis" post="C including patients with decompensated cirrhosis •For drug-interaction details"/>
 <result pre="binding to SARS-CoV-2 RdRp44 •Good experience in patients with chronic" exact="hepatitis" post="C including patients with decompensated cirrhosis •For drug-interaction details"/>
 <result pre="in patients with chronic hepatitis C including patients with decompensated" exact="cirrhosis" post="•For drug-interaction details see45 •Ribavirin may cause severe haemolytic"/>
 <result pre="decompensated cirrhosis •For drug-interaction details see45 •Ribavirin may cause severe" exact="haemolytic anaemia" post="Baricitinib∗ •Janus kinase inhibitor, might interrupt endocytosis of the"/>
 <result pre="cirrhosis •For drug-interaction details see45 •Ribavirin may cause severe haemolytic" exact="anaemia" post="Baricitinib∗ •Janus kinase inhibitor, might interrupt endocytosis of the"/>
 <result pre="assembly of virus particles46 •Could affect both inflammation and cellular" exact="viral" post="entry •Associated with transient and usually mild elevations of"/>
 <result pre="•Could affect both inflammation and cellular viral entry •Associated with" exact="transient" post="and usually mild elevations of ALT47 •Patients with decompensated"/>
 <result pre="transient and usually mild elevations of ALT47 •Patients with decompensated" exact="cirrhosis" post="should not be treated Camostat∗ •Blocks serine protease TMPRSS2"/>
 <result pre="for S protein priming48 •Licensed in Japan for treatment of" exact="chronic" post="pancreatitis •Patients with chronic viral hepatitis and cirrhosis are"/>
 <result pre="S protein priming48 •Licensed in Japan for treatment of chronic" exact="pancreatitis" post="•Patients with chronic viral hepatitis and cirrhosis are excluded"/>
 <result pre="•Licensed in Japan for treatment of chronic pancreatitis •Patients with" exact="chronic" post="viral hepatitis and cirrhosis are excluded from clinical trial"/>
 <result pre="in Japan for treatment of chronic pancreatitis •Patients with chronic" exact="viral hepatitis" post="and cirrhosis are excluded from clinical trial for chronic"/>
 <result pre="Japan for treatment of chronic pancreatitis •Patients with chronic viral" exact="hepatitis" post="and cirrhosis are excluded from clinical trial for chronic"/>
 <result pre="treatment of chronic pancreatitis •Patients with chronic viral hepatitis and" exact="cirrhosis" post="are excluded from clinical trial for chronic pancreatitis.49 •Drug-interactions"/>
 <result pre="viral hepatitis and cirrhosis are excluded from clinical trial for" exact="chronic" post="pancreatitis.49 •Drug-interactions unknown Emapalumab∗ •mAb targeting interferon-gamma •Treat cytokine"/>
 <result pre="pancreatitis.49 •Drug-interactions unknown Emapalumab∗ •mAb targeting interferon-gamma •Treat cytokine release" exact="syndrome" post="observed in COVID-197 •Approved for haemophagocytic lymphohistiocytosis •Clinical trial"/>
 <result pre="lymphohistiocytosis •Clinical trial for COVID-19 planned50 •Associated with mild and" exact="transient" post="ALT elevations typically arising a few weeks after start"/>
 <result pre="start of treatment •Risk of reactivation of tuberculosis, pneumocystis jirovecii," exact="herpes zoster" post="•Risk of HBV reactivation may be lower Anakinra∗ •Interleukin"/>
 <result pre="of treatment •Risk of reactivation of tuberculosis, pneumocystis jirovecii, herpes" exact="zoster" post="•Risk of HBV reactivation may be lower Anakinra∗ •Interleukin"/>
 <result pre="pneumocystis jirovecii, herpes zoster •Risk of HBV reactivation may be" exact="lower" post="Anakinra∗ •Interleukin 1 receptor antagonist •Clinical trial for COVID-19"/>
 <result pre="treatment recommendations. The evidence to use these drugs is low." exact="Multiple" post="RCTs for the above-mentioned drugs and some other drugs"/>
 <result pre="angiotensin-converting enzyme 2; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19," exact="coronavirus disease" post="2019; NUC, nucleoside analogue; PIs, protease inhibitors; RdRp, RNA-dependent"/>
 <result pre="enzyme 2; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus" exact="disease" post="2019; NUC, nucleoside analogue; PIs, protease inhibitors; RdRp, RNA-dependent"/>
 <result pre="analogue; PIs, protease inhibitors; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2. ∗These drugs are listed to"/>
 <result pre="PIs, protease inhibitors; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2. ∗These drugs are listed to include"/>
 <result pre="protease inhibitors; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2. ∗These drugs are listed to include the"/>
 <result pre="based on in vitro observations or their mode of action." exact="General" post="considerations for patients with chronic liver disease and COVID-19"/>
 <result pre="or their mode of action. General considerations for patients with" exact="chronic" post="liver disease and COVID-19 •Consider early admission according to"/>
 <result pre="their mode of action. General considerations for patients with chronic" exact="liver disease" post="and COVID-19 •Consider early admission according to the presence"/>
 <result pre="mode of action. General considerations for patients with chronic liver" exact="disease" post="and COVID-19 •Consider early admission according to the presence"/>
 <result pre="acetaminophen overdosing (2–3 g/day is considered safe in patients with" exact="cirrhosis" post="without active alcohol consumption33) •Do not administer non-steroidal anti-inflammatory"/>
 <result pre="consumption33) •Do not administer non-steroidal anti-inflammatory drugs in patients with" exact="cirrhosis" post="and portal hypertension33 •See also section on &quot;liver-related diagnostic"/>
 <result pre="HCC surveillance and liver biopsy Specific considerations for patients with" exact="chronic" post="liver disease and COVID-19 •In patients with decompensated cirrhosis,"/>
 <result pre="surveillance and liver biopsy Specific considerations for patients with chronic" exact="liver disease" post="and COVID-19 •In patients with decompensated cirrhosis, treatment for"/>
 <result pre="and liver biopsy Specific considerations for patients with chronic liver" exact="disease" post="and COVID-19 •In patients with decompensated cirrhosis, treatment for"/>
 <result pre="patients with decompensated cirrhosis, treatment for cirrhosis-associated complications such as" exact="portal hypertension," post="ascites, hepatic encephalopathy, spontaneous bacterial peritonitis etc. should be"/>
 <result pre="cirrhosis-associated complications such as portal hypertension, ascites, hepatic encephalopathy, spontaneous" exact="bacterial" post="peritonitis etc. should be continued. •In patients with HCC,"/>
 <result pre="complications such as portal hypertension, ascites, hepatic encephalopathy, spontaneous bacterial" exact="peritonitis" post="etc. should be continued. •In patients with HCC, locoregional"/>
 <result pre="disclosure forms for further details. References References 1GuanW.J.NiZ.Y.HuY.LiangW.H.OuC.Q.HeJ.X.Clinical characteristics of" exact="coronavirus disease" post="2019 in ChinaN Engl J Med2020[Epub ahead of print]"/>
 <result pre="forms for further details. References References 1GuanW.J.NiZ.Y.HuY.LiangW.H.OuC.Q.HeJ.X.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med2020[Epub ahead of print]"/>
 <result pre="of print] 2ZhouF.YuT.DuR.FanG.LiuY.LiuZ.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="and clinical relevanceJ Hepatol6120141385139625135860 5XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med2020[Epub ahead of print] 6LiX.GengM.PengY.MengL.LuS.Molecular"/>
 <result pre="clinical relevanceJ Hepatol6120141385139625135860 5XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med2020[Epub ahead of print] 6LiX.GengM.PengY.MengL.LuS.Molecular immune"/>
 <result pre="8YangX.YuY.XuJ.ShuH.XiaJaLiuH.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir"/>
 <result pre="highly pathogenic human coronavirus infectionsLiver Int2020[Epub ahead of print] 11SchütteA.CiesekS.WedemeyerH.LangeC.M.Influenza" exact="virus infection" post="as precipitating event of acute-on-chronic liver failureJ Hepatol70201979779930635243 12WallsA.C.ParkY.-J.TortoriciM.A.WallA.McGuireA.T.VeeslerD.Structure,"/>
 <result pre="pathogenic human coronavirus infectionsLiver Int2020[Epub ahead of print] 11SchütteA.CiesekS.WedemeyerH.LangeC.M.Influenza virus" exact="infection" post="as precipitating event of acute-on-chronic liver failureJ Hepatol70201979779930635243 12WallsA.C.ParkY.-J.TortoriciM.A.WallA.McGuireA.T.VeeslerD.Structure,"/>
 <result pre="infectionbioRxiv2020 14XuH.ZhongL.DengJ.PengJ.DanH.ZengX.High expression of ACE2 receptor of 2019-nCoV on the" exact="epithelial" post="cells of oral mucosaInt J Oral Sci122020832094336 15YeoC.KaushalS.YeoD.Enteric involvement"/>
 <result pre="requiring endoscopic surveillance for varicesJ Hepatol65201689990527388923 19ZhuL.XuX.MaK.YangJ.GuanH.ChenS.Successful recovery of COVID-19" exact="pneumonia" post="in a renal transplant recipient with long-term immunosuppressionAm J"/>
 <result pre="SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for" exact="infectious diseases" post="in Northern ItalyJ Hosp Infect2020[Epub ahead of print] 21GodoyP.TornerN.SoldevilaN.RiusC.JaneM.MartínezA.Hospital-acquired"/>
 <result pre="in Northern ItalyJ Hosp Infect2020[Epub ahead of print] 21GodoyP.TornerN.SoldevilaN.RiusC.JaneM.MartínezA.Hospital-acquired influenza" exact="infections" post="detected by a surveillance system over six seasons, from"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends1412020727332074550 30LiG.De ClercqE.Therapeutic options for the"/>
 <result pre="novel coronavirus (2019-nCoV)Nat Rev Drug Discov19202014915032127666 31DongL.HuS.GaoJ.Discovering drugs to treat" exact="coronavirus disease" post="2019 (COVID-19)Drug Discoveries Ther1420205860 32GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and azithromycin as a"/>
 <result pre="coronavirus (2019-nCoV)Nat Rev Drug Discov19202014915032127666 31DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discoveries Ther1420205860 32GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and azithromycin as a"/>
 <result pre="analogs as a promising strategy for the treatment of emerging" exact="viral" post="diseasesPharmacol Res Perspect52017e0029328596841 37YoungB.E.OngS.W.X.KalimuddinS.LowJ.G.TanS.Y.LohJ.Epidemiologic features and clinical course of"/>
 <result pre="data in rheumatoid arthritisArthritis Rheumatol6920171751176128597609 40ChenL.-F.MoY.-Q.JingJ.MaJ.-D.ZhengD.-H.DaiL.Short-course tocilizumab increases risk of" exact="hepatitis" post="B virus reactivation in patients with rheumatoid arthritis: a"/>
 <result pre="clinical observationInt J Rheum Dis20201785986928160426 41WHO. Clinical management of severe" exact="acute" post="respiratory infection (SARI) when COVID-19 disease is suspected. 2020."/>
 <result pre="observationInt J Rheum Dis20201785986928160426 41WHO. Clinical management of severe acute" exact="respiratory" post="infection (SARI) when COVID-19 disease is suspected. 2020. Available"/>
 <result pre="J Rheum Dis20201785986928160426 41WHO. Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected. 2020. Available from:"/>
 <result pre="Clinical management of severe acute respiratory infection (SARI) when COVID-19" exact="disease" post="is suspected. 2020. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. [Accessed 18 March"/>
 <result pre="[Accessed 20 March 2020]. 46RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet3952020e30e3132032529 47MarkhamA.Baricitinib: first global approvalDrugs77201769770428290136 48HoffmannM.Kleine-WeberH.SchroederS.KrügerN.HerrlerT.ErichsenS.SARS-CoV-2 cell entry"/>
 <result pre="20 March 2020]. 46RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet3952020e30e3132032529 47MarkhamA.Baricitinib: first global approvalDrugs77201769770428290136 48HoffmannM.Kleine-WeberH.SchroederS.KrügerN.HerrlerT.ErichsenS.SARS-CoV-2 cell entry depends"/>
 <result pre="the pharmacokinetics, safety, and efficacy of NI-03 in patients with" exact="chronic" post="pancreatitis: study protocol for a randomized controlled trial on"/>
 <result pre="randomized controlled trial on the assessment of camostat treatment in" exact="chronic" post="pancreatitis (TACTIC)Trials20201950131412955 50Press release on planned clinical trials to"/>
 <result pre="controlled trial on the assessment of camostat treatment in chronic" exact="pancreatitis" post="(TACTIC)Trials20201950131412955 50Press release on planned clinical trials to evaluate"/>
</results>
